Agilent Technologies, Inc.

NYSE A

Agilent Technologies, Inc. Price to Book Ratio (P/B) on January 14, 2025: 6.77

Agilent Technologies, Inc. Price to Book Ratio (P/B) is 6.77 on January 14, 2025, a 1.15% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Agilent Technologies, Inc. 52-week high Price to Book Ratio (P/B) is 7.51 on May 20, 2024, which is 10.99% above the current Price to Book Ratio (P/B).
Agilent Technologies, Inc. 52-week low Price to Book Ratio (P/B) is 6.01 on November 19, 2024, which is -11.27% below the current Price to Book Ratio (P/B).
Agilent Technologies, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 6.71.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NYSE: A

Agilent Technologies, Inc.

CEO	Mr. Rodney Gonsalves
IPO Date	Nov. 18, 1999
Location	United States
Headquarters	5301 Stevens Creek Boulevard
Employees	17,400
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Key trends

Past 5 years